Chaperonin containing TCP1 subunit 6A may activate Notch and Wnt pathways to facilitate the malignant behaviors and cancer stemness in oral squamous cell carcinoma

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–10. doi:10.3322/caac.21660.
   PubMed Web of Science ®Google Scholar
• Fritz C, Ng JJ, Harris J, Romeo DJ, Prasad A, Moreira A, Rajasekaran K. Clinical practice guidelines for management of head and neck squamous cell carcinoma of unknown primary: an AGREE II appraisal. Eur Arch Otorhinolaryngol. 2023;280(9):4195–4204. doi:10.1007/s00405-023-07997-9.
   PubMed Web of Science ®Google Scholar
• Chamoli A, Gosavi AS, Shirwadkar UP, Wangdale KV, Behera SK, Kurrey NK, Kalia K, Mandoli A. 2021. Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics. Oral Oncol. 121:105451. doi:10.1016/j.oraloncology.2021.105451.
   PubMed Web of Science ®Google Scholar
• Yang SY, Li SH, Liu JL, Sun XQ, Cen YY, Ren RY, Ying SC, Chen Y, Zhao ZH, Liao W. Histopathology-based diagnosis of oral squamous cell carcinoma using deep learning. J Dent Res. 2022;101(11):1321–1327. doi:10.1177/00220345221089858.
   PubMed Web of Science ®Google Scholar
• Shetty KSR, Kurle V, Greeshma P, Ganga VB, Murthy SP, Thammaiah SK, Prasad PK, Chavan P, Halkud R, Krishnappa R. 2021. Salvage Surgery in recurrent oral squamous cell carcinoma. Front Oral Health. 2:815606. doi:10.3389/froh.2021.815606.
   PubMedGoogle Scholar
• Kain JJ, Birkeland AC, Udayakumar N, Morlandt AB, Stevens TM, Carroll WR, Rosenthal EL, Warram JM. Surgical margins in oral cavity squamous cell carcinoma: Current practices and future directions. Laryngoscope. 2020;130(1):128–138. doi:10.1002/lary.27943.
   PubMed Web of Science ®Google Scholar
• Chakraborty R, Darido C, Liu F, Maselko M, Ranganathan S. Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research. Cancers Basel. 2023;15(3). doi:10.3390/cancers15030852.
   Web of Science ®Google Scholar
• Willison KR. The substrate specificity of eukaryotic cytosolic chaperonin CCT. Philos Trans R Soc Lond B Biol Sci. 2018;373(1749):20170192. doi:10.1098/rstb.2017.0192.
   PubMed Web of Science ®Google Scholar
• Zheng L, Chen X, Zhang L, Qin N, An J, Zhu J, Jin H, Tuo B. A potential tumor marker: chaperonin containing TCP‑1 controls the development of malignant tumors (review). Int J Oncol. 2023;63(3). doi:10.3892/ijo.2023.5554.
   Web of Science ®Google Scholar
• Ying Z, Tian H, Li Y, Lian R, Li W, Wu S, Zhang HZ, Wu J, Liu L, Song J, et al. CCT6A suppresses SMAD2 and promotes prometastatic TGF-beta signaling. J Clin Invest. 2017;127(5):1725–1740. doi:10.1172/JCI90439.
   PubMed Web of Science ®Google Scholar
• Zeng G, Wang J, Huang Y, Lian Y, Chen D, Wei H, Lin C, Huang Y. 2019. Overexpressing CCT6A contributes to cancer cell growth by affecting the G1-to-S phase transition and predicts a negative prognosis in hepatocellular carcinoma. Onco Targets Ther. 12:10427–10439. doi:10.2147/OTT.S229231.
   PubMed Web of Science ®Google Scholar
• Zeng W, Wu M, Cheng Y, Liu L, Han Y, Xie Q, Li J, Wei L, Fang Y, Chen Y, et al. CCT6A knockdown suppresses osteosarcoma cell growth and Akt pathway activation in vitro. PLoS ONE. 2022;17(12):e0279851. doi:10.1371/journal.pone.0279851.
   PubMed Web of Science ®Google Scholar
• Xia X, Zhao S, Chen W, Xu C, Zhao D. CCT6A promotes esophageal squamous cell carcinoma cell proliferation, invasion and epithelial-mesenchymal transition by activating TGF-beta/Smad/c-myc pathway. Ir J Med Sci. 2023. doi:10.1007/s11845-023-03357-y.
   Web of Science ®Google Scholar
• Yang X, Tong Y, Ye W, Chen L. HOXB2 increases the proliferation and invasiveness of colon cancer cells through the upregulation of CCT6A. Mol Med Rep. 2022;25(5). doi:10.3892/mmr.2022.12690.
   Web of Science ®Google Scholar
• Peng X, Chen G, Lv B, Lv J. MicroRNA-148a/152 cluster restrains tumor stem cell phenotype of colon cancer via modulating CCT6A. Anticancer Drugs. 2022;33(1):e610–e21. doi:10.1097/CAD.0000000000001198.
   PubMed Web of Science ®Google Scholar
• Peng S, Yu J, Wang Y. 2023. CCT6A dysregulation in surgical prostate cancer patients: association with disease features, treatment information, and prognosis. Ir J Med Sci. doi:10.1007/s11845-023-03461-z
   Web of Science ®Google Scholar
• Wang H, Wang X, Xu L, Lin Y, Zhang J, Yang Y. 2022. CCT6A and CHCHD2 are coamplified with EGFR and associated with the unfavorable Clinical outcomes of lung adenocarcinoma. Dis Markers. 2022:1–16. doi:10.1155/2022/1560199.
   Web of Science ®Google Scholar
• Hu J, Han C, Zhong J, Liu H, Liu R, Luo W, Chen P, Ling F. 2021. Dynamic network biomarker of pre-exhausted CD8(+) T cells contributed to T cell exhaustion in colorectal cancer. Front Immunol. 12:691142. doi:10.3389/fimmu.2021.691142.
   PubMed Web of Science ®Google Scholar
• Head SR, Komori HK, LaMere SA, Whisenant T, Van Nieuwerburgh F, Salomon DR, Ordoukhanian P. 2014. Library construction for next-generation sequencing: overviews and challenges. Biotechniques. 56(2):61–64. 66, 68, passim. doi: 10.2144/000114133
   PubMed Web of Science ®Google Scholar
• Xie J, Huang L, Lu YG, Zheng DL. 2020. Roles of the Wnt signaling pathway in head and neck squamous cell carcinoma. Front Mol Biosci. 7:590912. doi:10.3389/fmolb.2020.590912.
   PubMed Web of Science ®Google Scholar
• Liu W, Shi X, Wang B. Retraction note: microRNA-133a exerts tumor suppressive role in oral squamous cell carcinoma through the Notch signaling pathway via downregulation of CTBP2. Cancer Gene Ther. 2023;30(8):1179–1179. doi:10.1038/s41417-023-00649-4.
   PubMed Web of Science ®Google Scholar
• Roh SH, Kasembeli M, Bakthavatsalam D, Chiu W, Tweardy DJ. Contribution of the type II Chaperonin, TRiC/CCT, to Oncogenesis. Int J Mol Sci. 2015;16(11):26706–26720. doi:10.3390/ijms161125975.
   PubMed Web of Science ®Google Scholar
• Andrade-Tomaz M, de Souza I, Rocha CRR, Gomes LR. The role of chaperone-mediated autophagy in cell cycle control and its implications in cancer. Cells. 2020;9(9):2140. doi:10.3390/cells9092140.
   PubMed Web of Science ®Google Scholar
• Chen X, Chen X, Huang Y, Lin J, Wu Y, Chen Y. TCP1 increases drug resistance in acute myeloid leukemia by suppressing autophagy via activating AKT/mTOR signaling. Cell Death Disease. 2021;12(11):1058. doi:10.1038/s41419-021-04336-w.
   PubMed Web of Science ®Google Scholar
• Ghozlan H, Showalter A, Lee E, Zhu X, Khaled AR. 2021. Chaperonin-containing TCP1 complex (CCT) promotes breast cancer growth through correlations with key cell cycle regulators. Front Oncol. 11:663877. doi:10.3389/fonc.2021.663877.
   PubMed Web of Science ®Google Scholar
• Huang K, Zeng Y, Xie Y, Huang L, Wu Y. Bioinformatics analysis of the prognostic value of CCT6A and associated signalling pathways in breast cancer. Mol Med Rep. 2019;19(5):4344–4352. doi:10.3892/mmr.2019.10100.
   PubMed Web of Science ®Google Scholar
• Kon M, Kiffin R, Koga H, Chapochnick J, Macian F, Varticovski L, Cuervo AM. Chaperone-mediated autophagy is required for tumor growth. Sci Transl Med. 2011;3(109):109ra17. doi:10.1126/scitranslmed.3003182.
   Web of Science ®Google Scholar
• Trinidad AG, Muller PA, Cuellar J, Klejnot M, Nobis M, Valpuesta JM, Vousden KH. Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol Cell. 2013;50(6):805–817. doi:10.1016/j.molcel.2013.05.002.
   PubMed Web of Science ®Google Scholar
• Ferreira A, Aster JC. 2022. Notch signaling in cancer: complexity and challenges on the path to clinical translation. Semin Cancer Biol. 85:95–106. doi:10.1016/j.semcancer.2021.04.008.
   PubMed Web of Science ®Google Scholar
• Porcheri C, Mitsiadis TA. Notch in head and neck cancer. Adv Exp Med Biol. 2021;1287:81–103. doi:10.1007/978-3-030-55031-8_7.
   PubMed Web of Science ®Google Scholar
• Weaver AN, Burch MB, Cooper TS, Della Manna DL, Wei S, Ojesina AI, Rosenthal EL, Yang ES. Notch signaling activation is associated with patient mortality and increased FGF1-mediated invasion in squamous cell carcinoma of the oral cavity. Mol Cancer Res. 2016;14(9):883–891. doi:10.1158/1541-7786.MCR-16-0114.
   PubMed Web of Science ®Google Scholar
• Kalafut J, Czerwonka A, Anameric A, Przybyszewska-Podstawka A, Misiorek JO, Rivero-Muller A, Nees M. Shooting at moving and hidden targets—tumour cell plasticity and the Notch signalling pathway in head and neck squamous cell carcinomas. Cancers Basel. 2021;13(24):6219. doi:10.3390/cancers13246219.
   PubMed Web of Science ®Google Scholar
• Lee SH, Do SI, Lee HJ, Kang HJ, Koo BS, Lim YC. Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma. Lab Invest. 2016;96(5):508–516. doi:10.1038/labinvest.2015.163.
   PubMed Web of Science ®Google Scholar
• MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. doi:10.1016/j.devcel.2009.06.016.
   PubMed Web of Science ®Google Scholar
• Chen S, Guttridge DC, You Z, Zhang Z, Fribley A, Mayo MW, Kitajewski J, Wang CY. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol. 2001;152(1):87–96. doi:10.1083/jcb.152.1.87.
   PubMed Web of Science ®Google Scholar
• Liu SC, Huang CS, Huang CM, Hsieh MS, Huang MS, Fong IH, Yeh CT, Lin CC. 2021. Isoorientin inhibits epithelial-to-mesenchymal properties and cancer stem-cell-like features in oral squamous cell carcinoma by blocking Wnt/beta-catenin/STAT3 axis. Toxicol Appl Pharmacol. 424:115581. doi:10.1016/j.taap.2021.115581.
   PubMed Web of Science ®Google Scholar
• Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik SR, Arya R, Rath R, Das Majumdar SK, Muduly DK, et al. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3beta axis. JCI Insight. 2021. 6(4). doi:10.1172/jci.insight.143643.
   PubMed Web of Science ®Google Scholar